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Background: To construct the Bifidobacterium infantis-mediated soluble kinase insert domain receptor (sKDR)
prokaryotic expression system and to observe its inhibitory effect on growth of human umbilicus vessel endothelial
cells (HUVECs) in vitro and Lewis lung cancer (LLC) on mice in vivo.
Methods: The Bifidobacterium infantis-mediated sKDR prokaryotic expression system was constructed through
electroporation and subsequently identified through PCR and Western blot analysis. HUVECs were added to the
products of this system to evaluate the anti-angiogenesis effect through MTT assay in vitro. The LLC mice models
were divided into three groups: one group treated with saline (group a); one group treated with recombinant
Bifidobacterium infantis containing pTRKH2-PsT plasmid group (group b); and one group treated with recombinant
Bifidobacterium infantis containing pTRKH2-PsT/sKDR plasmid group (group c). The quality of life and survival of
mice were recorded. Tumor volume, tumor weight, inhibitive rate, and necrosis rate of tumor were also evaluated.
Necrosis of tumor and signals of blood flow in tumors were detected through color Doppler ultrasound. In addition,
microvessel density (MVD) of the tumor tissues was assessed through CD31 immunohistochemical analysis.
Results: The positively transformed Bifidobacterium infantis with recombinant pTRKH2-PsT/sKDR plasmid was
established, and was able to express sKDR at gene and protein levels. The proliferation of HUVECs cultivated with
the extract of positively transformed bacteria was inhibited significantly compared with other groups (P< 0. 05).
The quality of life of mice in group c was better than in group a and b. The recombinant Bifidobacterium infantis
containing pTRKH2-PsT/sKDR plasmid enhanced the efficacy of tumor growth suppression and prolongation of
survival, increased the necrosis rate of tumor significantly, and could obviously decrease MVD and the signals of
blood flow in tumors.
Conclusion: The Bifidobacterium infantis-mediated sKDR prokaryotic expression system was constructed successfully.
This system could express sKDR at gene and protein levels and significantly inhibit the growth of HUVECs induced
by VEGF in vitro. Moreover, it could inhibit tumor growth and safely prolong the survival time of LLC C57BL/6 mice.* Correspondence: yicheng6834@163.com; huangying68@163.com
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The growth, invasion, and metastasis of malignant tumors
are angiogenesis-dependent processes [1,2]. The anti-
angiogenesis study of tumor has become increasingly
popular after Folkman first proposed in 1971 that tumor
growth depends on new blood vessels [3,4]. To date, anti-
angiogenesis therapy has been proven effective by many
studies and has become an irreplaceable method for can-
cer treatment [4-8].
Vascular endothelial growth factor (VEGF) is the most
important factor for angiogenesis; it is secreted abun-
dantly in tumor tissues [9-11]. VEGF can bind specific-
ally to VEGFR (mainly VEGFR1 and VEGFR2) and
induce blood vessel formation. The blockage of this
binding process may significantly suppress the formation
of new blood vessels in the tumor, and then suppress
tumor growth, invasion, and metastasis [12,13]. The sol-
uble kinase insert domain receptor (sKDR) is a soluble
form of the extramembrane part of VEGFR2 [14]. It has
the same high affinity for VEGF but does not induce
angiogenesis [15]. Thus, the delivery of sKDR to tumor
tissues inhibits the formation of new blood vessels in the
tumor tissues and has an anti-tumor effect [6,16].
Deficiency of the specifically targeted vector is an im-
portant obstacle in cancer gene therapy [17]. Although
viruses and liposomes have been widely used as delivery
vectors, their lack of specific targeting property causes
massive distribution to untargeted tissues and results in
several side effects [18-21]. Thus, developing specific tar-
geting vectors is very important.
Bifidobacterium infantis is an anaerobic and non-
pathogenic bacterium that has been proven by our previ-
ous study to specifically target the anaerobic environ-
ment of tumor center [22]. The aim of this study was to
construct a Bifidobacterium infantis-mediated sKDR pro-
karyotic expression system and to observe its effect on
human umbilicus vessel endothelial cells (HUVECs) in vitro
and on Lewis lung cancer (LLC) mice model in vivo.
Methods
Materials
Strains of Bifidobacterium infantis 2001 were obtained
from the Key Laboratory of West China School of Sto-
matology, Sichuan University (China). PTRKH2-PsT
plasmid containing erythromycinr (Eryr) gene was pro-
vided by the Life Scientific College of Fudan University
(China). The LLC cell line was provided by the State Key
Laboratory of Biomedicine, Sichuan University (China).
Recombinant E. coli DH5α line containing pcDNA3.1/
sKDR was constructed in our laboratory [23]. Female
C57BL/6 mice (6 weeks to 8 weeks old) weighing be-
tween 16 and 18 g were purchased from the Experimen-
tal Animal Center of Sichuan University (China). DNA
Marker III was purchased from Tiangen (China) orTransgen (China). T4 DNA ligase, BamH I, Sal I, and
One-Step RNA PCR Kit were purchased from Takara
(Dalian, China). The plasmid purification kit, PCR prod-
uct purification kit, plasmid mini preparation kit, Wizard
PCR Preps DNA Purification System, and gel extraction
kit were purchased from Omega (USA). Mouse mono-
clonal antibody for sKDR was purchased from R&D
(USA). Polyvinylidene difluoride (PVDF) membranes
were purchased from Millipore (USA). The PCR reaction
test kit was purchased from Tiangen (China). Trizol re-
agent was purchased from Transgen (China). 3-(4,5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT), lysozyme, and trypsin were purchased from
Sigma (USA). Mouse monoclonal antibody for CD31 and
LSAB kit were purchased from Dako (Denmark). The
enhanced chemiluminescence (ECL) detection kit and X-
ray films were purchased from Roche (Switzerland).
Dulbecco's modified Eagle's medium (DMEM), M199
medium, and dimethylsulfoxide (DMSO) were purchased
from Gibco (USA).
Construction of recombinant plasmid
Strains of E. coli DH5α containing plasmid pTRKH2-PsT
were inoculated into 5 ml LB liquid medium with
300 μg/ml Ery and shaken overnight at 37°C for 12 hours.
Subsequently, plasmid pTRKH2-PsT was purified using a
plasmid purification kit (Omega Co.). Specific primers of
sKDR gene were designed based on published sequences
(GenBank, AF063658). The upstream primer was 5’-
CCGGGATCCATGGAGAGCAAGGTGCTG-3’ and the
downstream primer was 5’-GTGGTCGACTTTTTCATG
GACCCTGAC-3’. After an initial denaturation for 2 min
at 94°C, 3.0 μl DNA template was amplified for 35 cycles
of denaturation at 94°C for 30 s, annealed at 55°C for
30 s, with an extension at 72°C for 2 min, followed by a
final extension for 8 min at 72°C. The amplified products
were confirmed via electrophoresis on 0.9% agarose gel.
Approximately 9 μl sKDR gene and 3 μl pTRKH2-PsT
plasmid were digested by two restriction enzymes
(BamH I and Sal I), joined by T4 DNA ligase at 16°C for
12 h, and finally stored at −20°C. The recombinant
pTRKH2-PsT/sKDR plasmid was then separated through
electrophoresis to confirm whether the ligation products
had the desired size.
Transformation of bifidobacterium infantis by
electroporation
Bifidobacterium infantis were harvested and washed
after growth at 37°C and resuspended in 40 μl ice-chilled
sucrose solution with 1 mmol/L ammonium citrate.
About 40 μl suspension and electroporation was carried
out to transfect recombinant pTRKH2-PsT/sKDR into
Bifidobacterium infantis at 25 μF, 2.0 kV. The cuvette
was connected parallel to a 200 Ω resistor.
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The transformed Bifidobacterium infantis were culti-
vated in MRS plates with 10 μl Ery until the colonies
achieved 1 mm diameter. A single positively transformed
colony was selected and incubated at 37°C in 5 ml Eryr
MRS liquid medium for 12 h. The plasmid DNA was
extracted and digested by BamH I (1 μl) and Sal I (1 μl)
at 37°C for 4 h. The products were then identified via
electrophoresis through 0.9% agarose gel. The identified
recombinant plasmid DNA was used as template and
amplified through PCR with specific primers of sKDR
gene. The amplified products were confirmed via elec-
trophoresis on 0.9% agarose gel. Sequencing was carried
out by Invitrogen Co. (Shanghai, China).
Detection of sKDR gene expression of recombinant
positive bifidobacterium infantis
The total RNA of recombinant positive colonies was
extracted using Trizol reagent. RT-PCR products were
synthesized using total RNA as template (30 times am-
plification cycle with the condition of denaturation at 94°C
for 30 s, annealing at 55°C for 30 s, and an extension at
72°C for 1 min). The amplified products were then
identified through 0.9% agarose gel electrophoresis.
The positively transformed Bifidobacteria infantis (100 μl)
were inoculated into 20 ml Eryr MRS liquid medium into
an anaerobic environment at 37°C for 24 h. The bacteria
were then harvested via centrifugation, resuspended in lysis
buffer (50 mM Tris·HCl, 2 mM EDTA, 100 mM NaCl, 0.5%
Triton X-100, 1 mg/ml lysozyme, pH 8.5), and sonicated.
Protein concentration was determined using the bicinchoni-
nic acid (BCA) method. Approximately 30 μg of protein
was subjected to 4% to 12% gradient SDS-PAGE using a
Tris-glycine system, and then the gel was electroblotted
onto PVDF membrane for 45 min. The membrane was sub-
sequently incubated with 5% non-fat dry milk in PBS for
1 h to block nonspecific binding sites, and then incubated
with the appropriate primary antibody concentration (1:200
dilution for sKDR) for 2 h at 37°C in 5% non-fat dry milk.
The membrane was subsequently rinsed in PBS and then
incubated for 2 h at 37°C with goat antimouse IgG-HRP at
1:2000 dilution. The membrane was rinsed and visualized
with ECL detection reagents after incubation.
Effect of recombinant bifidobacterium infantis on HUVECs
Recombinant Bifidobacterium infantis containing pTRKH2-
PsT/sKDR and pTRKH2-PsT plasmids were broken
through ultrasonic wave and purified via dialysis. HUVECs
were digested with 0.25% trypsin and then cultured in vitro.
They were then diluted and inoculated into a 96-well plate
at a concentration of 1 ×104 cells and a volume of 0.2 ml
per well in 40 wells. The 40 wells were randomized into 4
groups after cultivated in M199 medium containing fatal
bovine serum (10 wells per group): group 1 (negativecontrol group) added with 0.2 ml liquid medium; group 2
(VEGF group) added with 0.2 ml liquid medium contain-
ing VEGF (6 ng/ml); group 3 (pTRKH2-PsT + VEGF
group) added with final solution of recombinant Bifidobac-
terium infantis containing pTRKH2-PsT plasmid 0.2 ml
and VEGF (6 ng/ml); and group 4 (pTRKH2-PsT/sKDR+
VEGF group) added with final solution of recombinant
Bifidobacterium infantis containing pTRKH2-PsT/sKDR
plasmid (0.2 ml) and VEGF (6 ng/ml). Cells were incubated
at 37°C for 24 h, and then 0.02 ml MTT (5 mg/ml final
concentration) was added to each well after an additional
4 h of incubation to allow MTT to form formazan crystals
by reacting with metabolically active cells. Approximately
150 μl DMSO was added to each well to dissolve the for-
mazan crystals at 37°C for 10 min. The absorbance values
of the solution in each well were measured at 490 nm
using a microplate reader. Cell viability (%) = absorbance of
the treated group/absorbance of VEGF group × 100%.
Cell culture
LLC cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum plus ampicillin and streptomycin routinely, and
incubated in 5% CO2 at 37°C.
Animal experiment designation
All animal procedures were approved by the Animal Care
and Scientific Committee of Sichuan University. The tumor
tissues from LLC mice were triturated and prepared into
cell suspensions (dilution 1:5 with normal saline). The cells
harvested from xenografts were adjusted to a concentration
of 1 × 107/ml, and 0.2 ml cell suspensions were inoculated
subcutaneously into the armpit of right anterior superior
limbs of C57BL/6 mice. The mice were randomized into 3
groups (8 mice per group) after 7 days when the tumors
were palpable (2 mm to 4 mm diameter): the control group
(group a) injected with 0.4 ml saline through the caudal
vein, the recombinant Bifidobacterium infantis containing
pTRKH2-PsT plasmid group (group b) injected with
0.4 ml suspension of Bifidobacterium infantis containing
pTRKH2-PsT plasmid (1 × 108/ml) through caudal vein,
and the recombinant Bifidobacterium infantis containing
pTRKH2-PsT/sKDR plasmid group (group c) injected with
0.4 ml suspension of Bifidobacterium infantis containing
pTRKH2-PsT/sKDR plasmid (1 × 108/ml) through caudal
vein. The mice were successively treated with the same dose
of Bifidobacterium infantis every 3 days, which lasted for
21 days. The mice of the 3 groups were killed after 21 days
of treatment. The tumors were then excised and weighed.
Identification of targeting property and sKDR expression
in vivo
Another 18 LLC bearing mice were divided into 3 groups
and received the same treatment as mentioned above,
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tumor and other tissues were operated under sterile condi-
tions. Part of these tissues was homogenized using saline
into a concentration of 10%, respectively. Approximately
100 μl homogenate of all the tissues was cultured on MRS
plate medium with Ery 10 μg/ml, 0.05% cysteine hydro-
chloride, and 0.5 M sucrose, and then incubated into an
anaerobic environment at 37°C for 3 days. About 20 μg
protein extracted from the tumor tissue of each group was
subjected to 4% to 12% gradient SDS–PAGE using a Tris–
glycine system. The gel was subsequently electroblotted
onto PVDF membrane for 45 min. The membrane was
incubated with 5% non-fat dry milk in PBS for 1 h to block
nonspecific binding sites, and then incubated with the
appropriate primary antibody concentration (1:200 dilu-
tion for sKDR) for 2 h at 37°C in 5% non-fat dry milk. The
membrane was rinsed in PBS and incubated for 2 h at 37°C
with goat antimouse IgG-HRP at 1:2000 dilution. The
membrane was rinsed and visualized with ECL detection
reagents after incubation.
Tumor growth and inhibitive rate of tumor
The length, width, and weight of tumor were measured
using a slide caliper every three days. Tumor volume
(TV) was estimated using the formula: TV (mm3) =
(width2 × length)/2. Inhibitive rate of tumor was calculated
using the formula: inhibitive rate of tumor (%) = (1 - average
weight in treated group/average weight in control) × 100%
[24].
Necrosis rate and blood flow of tumor
The remaining mice in all groups underwent color Dop-
pler ultrasound before they were killed after 21 days of
treatment. The size, tumor shape, ultrasonic echo from
tumor inner to known liquefied tumor, and necrotic
tissues were detected under two-dimensional ultrasound
by color Doppler (ACUSON 1228ST) with 5 MHz
frequency.
The necrosis rate of tumor was determined using the
following formula [25]: necrosis rate of tumor = necrosis
area/whole area × 100% (necrosis area = the largest diam-
eter × the smallest diameter of the necrosis area; whole
area = the largest diameter × the smallest diameter of the
area).
Signals of blood flow of CDFI were classified into four
grades based on the criteria of Adler [26]: 0, no blood
flow signals detected within the tumor; I, minimal blood
flow (one or two dot-like or thin- and short-like blood
flow signals detected within the tumor); II, moderate
blood flow (up to three dot-like blood flow signals or
one longer blood flow signal detected within the tumor);
and III, abundant blood flow (more than five dot-like
blood flow signals or two longer blood flow signals
detected within the tumor).Microvessel density (MVD)
Tumor tissues were fixed immediately in 10% buffered
formalin phosphate and embedded in paraffin. Immuno-
histochemical staining was performed using EnVision
method. Briefly, the dewaxed, rehydrated sections (5 μm)
were treated with 0.3% hydrogen peroxide in methanol
for 15 min to block endogenous peroxidase activity, and
then washed three times with Tris–HCl buffered saline
(TBS). The sections were repaired in citric acid antigen
repair solution (pH 6.0) for 40 min followed by treat-
ment with primary antibody at 37°C for one night
(anti-CD31 diluted for 1:100). After washed by TBS, the
sections were treated with EnVisionTM diluted for 1:100
at 37°C for 45 min and washed with TBS. The sections
were then stained with 3,3'-diaminobenzidine (DAB)
under light-controlled microscope and counterstained
with hematoxylin. Finally, the sections were dehydrated,
fixed, and analyzed by light microscopy.
Microvessel density (MVD) of the tumor tissues was
assessed through CD31 immunohistochemical analysis
using antibodies to the endothelial marker CD31 and
determined according to the method of Weidner et al.
[27]. Briefly, the immunostained sections were initially
screened at low magnification (40×) to identify hot spots,
which are the areas of highest neovascularization. Any
yellow-brown stained endothelial cell or endothelial cell
cluster clearly separate from the adjacent microvessels,
tumor cells, and other connective tissue elements was
considered a single, countable microvessel. Within the
hot spot area, the stained microvessels were counted in a
single high-power (200×) field, and the average vessel
count in three hot spots was considered the value of
MVD. All counts were performed by three investigators
in a blinded manner. Microvessel counts were compared
between the observers and discrepant results were reas-
sessed. The consensus was used as the final score for
analysis [28].
Side effects, quality of life, and survival
Another 30 mice were allocated randomly to groups a, b,
and c as mentioned above (10 mice per group), with the
aim to observe the different survival rates among the
three groups. Side effects during the experiment, such as
loss of appetite, weight loss, mental state, reaction to
stimulation, behavior change, and ruffling of fur were
recorded, as well as the survival time of every mouse.
Statistical analysis
All statistical analyses were performed using SPSS 11.5
software package. TV, necrosis rate of tumor, and MVD
were analyzed through one-way ANOVA, followed by
the Student's t test. Data of tumor inhibitive rate was
analyzed via Chi-square test. Survival curves were con-
structed according to the Kaplan–Meier method and
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CDFI grade was analyzed using Kruskal–Wallis test. All
P values were two-sided and P< 0.05 was considered the
significant level of difference.Results
PCR amplification of sKDR gene
The amplified products of sKDR gene were detected using
0.8% agarose gel electrophoresis. The results showed that
a specific segment about 1 kb (Figure 1A) was observed,
which was almost the size of the sKDR gene (981 bp).Identification of PCR-amplified products and
enzyme-digested products and sequencing
The amplified products of pTRKH2-PsT/sKDR plasmid
were detected using 0.8% agarose gel electrophoresis,
where one fragment with size of approximately 1 kb was
obtained (Figure 1B). The size was almost the same as
that of the sKDR gene (981 bp).
The digested products of pTRKH2-PsT/sKDR plasmid
were detected through agarose gel electrophoresis as well.
The results showed that the recombinant positive
pTRKH2-PsT/sKDR plasmid was about 8 kb. Two seg-
ments of approximately 981 bp and 6.9 kb extracted from
the 8 kb recombinant plasmid (Figure 1B) were equal to the
size of sKDR gene and pTRKH2-PsT plasmid, respectively.
Sequencing results showed that the size and sequence
of the nucleotide acid of the inserted gene segment were
completely consistent with the size and sequence of the
nucleotide acid of sKDR gene (GenBank: AF063658).
The full length of the inserted gene fragment was
981 bp. The sequence of two ends of the inserted gene
was also consistent with BamH I site and Sal I site. The
sequencing identified that the foreign gene (sKDR gene)
was correctly inserted into pTRKH2-PsT plasmid and
transferred into Bifidobacterium infantis. The findingsFigure 1 Results of electrophoresis and Western blot. (A) PCR products
digestion and PCR products. Lane 1: DNA Ladder; Lane 2: digestion of reco
pTRKH2-PsT/sKDR; Lane 4: plasmid pTRKH2-PsT; Lane 5: PCR products of sKD
products of sKDR gene from recombinant plasmid pcDNA3.1/sKDR; Lane 7:
Bifidobacterium infantis of pTRKH2-PsT/sKDR. Lane 1: PCR products of sKDR
product of RNA purified from Bifidobacterium infantis with pTRKH2-PsT/sKD
Lane 1: pTRKH2-PsT/sKDR; Lane 2: pTRKH2-PsT.showed that the targeting gene therapy system of Bifido-
bacterium infantis was successfully constructed.Detection of sKDR gene expression of recombinant
positive bifidobacterium infantis
The RT-PCR electrophoresis results of the positively
transformed Bifidobacterium infantis showed that there
was a specific segment of about 1 kb (Figure 1C), prov-
ing that the sKDR gene could replicate in recombinant
Bifidobacterium infantis.
The expression of sKDR protein from positively trans-
formed Bifidobacterium infantis was assayed via Western
blot analysis using a mouse monoclonal antibody for
sKDR. The results showed that there was a Western blot
band from the Bifidobacterium infantis-transformed
recombinant pTRKH2-PsT/sKDR plasmid (Figure 1D),
which is consistent with the size predicted by Expasy
proteomics tools (36.61 kD). In addition, there was no
similar band from Bifidobacterium infantis-transformed
recombinant pTRKH2-PsT plasmid (Figure 1D). This ob-
servation proved that sKDR could be expressed at the
protein level in Bifidobacterium infantis-transformed re-
combinant pTRKH2-PsT/sKDR plasmid.Effect of final solution of recombinant positive
Bifidobacterium infantis on the growth of HUVECs induced
by VEGF
After treated with the final solution of recombinant posi-
tive Bifidobacterium infantis for 24 h, the growth of
HUVECs induced by VEGF was significantly inhibited.
Only a few grew along the wall, and many cells floated in
the medium. The remaining cells underwent significant
changes in morphology: the original shape was gone, the
cytoplasm became rougher, the nucleus showed pycnosis,
and the refraction decreased, demonstrating obvious cellu-
lar damages. By contrast, HUVECs treated with negativeof sKDR. Lane 1: sKDR; Lane 2: DNA Marker III. (B) Endonuclease
mbinant plasmid pTRKH2-PsT/sKDR; Lane 3: recombinant plasmid
R gene from recombinant plasmid pTRKH2-PsT/sKDR; Lane 6: PCR
DNA Marker. (C) RT-PCR and PCR products from recombinant
gene from recombinant plasmid pTRKH2-PsT/sKDR; Lane 2: RT-PCR
R; Lane 3: DNA Marker. (D) Western blot analysis of sKDR expression.
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compared with the control. Figure 2 shows that the cell via-
bility of groups 2 and 3 had no significant difference (P>
0.05). However, the cell viability of groups 1 and 4 were
significantly lower than that of group 2 (P< 0.05). The
results showed that the VEGF could induce the growth of
HUVECs significantly and that the final solution of recom-
binant positive Bifidobacterium infantis could inhibit the
growth of HUVECs induced by VEGF.
Specific targeting of recombinant Bifidobacterium infantis
and sKDR expression in tumor tissue
Three days after incubation, a lot of white colonies were
found in the medium culturing tumor tissue, whereas no
colony was observed growing in the medium culturing
other tissues, such as heart, lung, liver, spleen, and kidney
(Figure 3A). These data showed that both the recombinant
Bifidobacterium infantis containing pTRKH2-PsT/sKDR
plasmid and pTRKH2-PsT plasmid had good targeting
property to tumor tissues. Thus, Bifidobacterium infantis
has the capability to specifically target the tumor tissue.
The findings in the Western blot (Figure 3B) showed
that a band about 36.61 kD from Bifidobacterium infan-
tis transformed the recombinant pTRKH2-PsT/sKDR
plasmid. The same band was not shown in the saline
control group or Bifidobacterium infantis-transformed
recombinant pTRKH2-PsT.
Tumor volume, tumor weight, and inhibitive rate of tumor
The treatment began on the seventh day after the mice
were injected with tumor cells. The volume and weight
of tumors were recorded, and the acceleration curve was
depicted (Figure 4). Figure 4 shows that the tumorFigure 2 Effect of Bifidobacterium infantis-mediated pTRKH2-PsT/sKDR
and final solution of Bifidobacterium infantis transformed with pTRKH2-PsT p
transformed with recombinant pTRKH2-PsT/sKDR plasmid.*P< 0.05 vs. VEGFvolume of groups b and c were smaller than that of
group a (P< 0.05), whereas the tumor volume in group
c was lower than that in group b (P< 0.05). The data of
tumor weight showed that the tumor weight of groups b
and c were smaller than that of group a (P< 0.05), espe-
cially group c (P< 0.05) (Figure 5A). In addition, the
inhibitive rate of tumor in groups b and c showed signifi-
cant increase compared with that in group a (P< 0.05),
and much more in group c (P< 0.05) (Figure 5B). All
the results above showed that Bifidobacterium infantis
containing pTRKH2-PsT/sKDR plasmid and pTRKH2-
PsT plasmid could inhibit the growth of tumor. The
Bifidobacterium infantis containing pTRKH2-PsT/sKDR
plasmid exhibited more significant effect.
Tumor necrosis rate
The necrotic areas of tumor showed low or no echo
through the color Doppler ultrasound. Massive necrotic
areas were observed in tumors of group c, with tumor ne-
crosis rate of (54.25 ± 6.86) %. Small necrotic areas were
observed in groups a and b, and the tumor necrosis rate
were (17.62 ± 4.90) % and (22.75 ± 5.73) %, respectively.
The tumor necrosis rate of group c was significantly larger
than that of the groups a and b (P< 0.05) (Figure 6).
Signal of blood flow in tumor
The color Doppler flow imaging showed that signals of
blood flow in tumor were the worst in group c and the
best in the control group (Figure 7). The signals of blood
flow were mainly level 0–I (7/8) in the group c, whereas
100% at level II or level III (8/8) in the control group.
The signals of blood in group b were intermediate be-
tween groups a and c.delivery system on HUVECs. 1: negative control; 2: VEGF; 3: VEGF
lasmid; 4: VEGF and final solution of Bifidobacterium infantis
group; ▲P< 0.05 vs. negative control.
Figure 3 Targeting property and sKDR expression. (A) Targeting property of Bifidobacterium infantis; (B) Expression of sKDR in tumor tissue.
Saline: saline control group; pTRKH2-PsT/sKDR: recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDR plasmid group; pTRKH2-PsT:
recombinant Bifidobacterium infantis containing pTRKH2-PsT plasmid group.
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MVD was estimated by counting the number of the
microvessels per high-power field (hpf) in the section
with an antibody reactive to CD31 (Figure 8). The data
showed that the MVD of group c was (11.6 ± 4.44)/vision
(200×), whereas that of groups a and b were (33.4 ± 3.66)/
vision (200×) and (30.0 ± 4.21)/vision (200×), respectively.Figure 4 Tumor growth curve. a: saline control group; b: recombinant Bif
recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDR plasmidThe MVD in group c is significantly lower than that in
groups a and b (P< 0.05), whereas no statistical signifi-
cance was observed between groups a and b (P> 0.05).
Side effects, survival quality, and analysis
Slight syndromes, such as bad appetite, stunted response,
little activity, and colorless fur on the 12th day wereidobacterium infantis containing pTRKH2-PsT plasmid group; c:
group. *P< 0.05 vs. group a; ▲P< 0.05 vs. group b.
Figure 5 Tumor weight and inhibitive rate of tumor. (A) Tumor weight; (B) Inhibitive rate of tumor. a: saline control group; b: recombinant
Bifidobacterium infantis containing pTRKH2-PsT plasmid group; c: recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDR plasmid group.
*P< 0.05 vs. group a; ▲P< 0.05 vs. group b.
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more evident over time. However, no significant differ-
ences were found among each group in mental status,
appetite, weight, and so on.Figure 6 Tumor necrosis. (A) Ultrasound images of tumor; (B) Necrosis ra
infantis containing pTRKH2-PsT plasmid group; c: recombinant Bifidobacteriu
shows the necrotic area. *P< 0.05 vs. group a; ▲P< 0.05 vs. group b.The mouse in the saline control group began to die on
the 29th day after the treatment, and all them died on
the 41st day because of tumor deterioration, excluding
improper experimental manipulation by mice anatomy.te of tumor. a: saline control group; b: recombinant Bifidobacterium
m infantis containing pTRKH2-PsT/sKDR plasmid group. The arrow
Figure 7 Tumor blood flow. (A) Blood flow image of tumor; (B) Classification of blood flow signals. a: saline control group; b: recombinant
Bifidobacterium infantis containing pTRKH2-PsT plasmid group; c: recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDR plasmid group.
Grade: 0, no blood flow signals were detected within the tumor; I, minimal blood flow (one or two dot-like or thin- and short-like blood flow signals
detected within the tumor); II, moderate blood flow (up to three dot-like blood flow signals or one longer blood flow signals detected within the
tumor); III, abundant blood flow (more than five dot-like blood flow signals or two longer blood flow signals detected within the tumor).
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were still alive on the 41st day, respectively (Figure 9). The
survival in group c was significantly prolonged (P< 0.05)
compared with that in groups a and b, whereas no statistical
significance was found between groups a and b (P> 0.05).
Discussion
Target gene therapy is one of the promising treatments
of cancer due to its high effectiveness and safety [17,29].
However, a crucial difficulty in performing this therapy is
the lack of specific delivery system [29,30]. Hypoxic
regions are characteristics of solid tumors in rodents and
occur with high frequency in many types of human
tumors. Tissue oxygen electrode measurements taken in
cancer patients show a median range of oxygen partial
pressure of 10 mmHg to 30 mmHg in tumors, with a
significant proportion of readings below 2.5 mmHg,
whereas those in normal tissues range from 24 mmHg to
66 mmHg [31,32]. The hypoxic environment advocates a
basis for using anaerobe as specific delivery carrier.Bifidobacterium infantis is a kind of Bifidobacteria that
is strictly anaerobic [22]. Many studies have found that
they could specifically target to the anaerobic environ-
ment of the tumor center. Kimura et al. [33] injected
Bifidobacterium bifidum intravenously into tumor-
bearing mice to study its specific targeting property.
They sacrificed the mice 48 and 96 hours after the injec-
tion and cultured the tumor tissue and other tissues.
Kimura et al. [33] found that there were massive Bifido-
bacterium bifidum growing in the tumor tissue and no
bacteria growing in other tissues, such as liver, spleen,
kidney, lung, blood, bone marrow, muscle, and so on.
Yazawa et al. [34] used Bifidobacterium longum as
delivery system for gene therapy on tumor-bearing mice.
They sacrificed 6 to 8 mice on 1, 2, 3, 4, and 7 days after
the treatment,and cultured the lung, liver, spleen,
kidney, heart, and tumor tissues. They found that Bifido-
bacterium longum could only specifically target the
tumor tissue. In this study, the tumor and other tissues
were also cultured after the mice were sacrificed. Many
Figure 8 Microvessel density (MVD). (A) Photomicrograph of immunohistochemical staining of CD31 (200×); (B) MVD. a: saline control group;
b: recombinant Bifidobacterium infantis containing pTRKH2-PsT plasmid group; c: recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDR
plasmid group. *P< 0.05 vs. group a; ▲P< 0.05 vs. group b. The arrows are directed to the vessels.
Li et al. BMC Cancer 2012, 12:155 Page 10 of 12
http://www.biomedcentral.com/1471-2407/12/155white colonies were observed in the medium culturing
tumor tissue, whereas no colony was found growing in
the medium culturing other tissues, such as heart, liver,
lung, kidney, and spleen. Thus, Bificobacterium infantisFigure 9 Survival curve of tumor-bearing mice. a: saline control group;
group; c: recombinant Bifidobacterium infantis containing pTRKH2-PsT/sKDRhas a very good targeting property to the anaerobic en-
vironment of tumor tissues.
Bifidobacterium infantis is a Gram-positive, domestic,
and non-pathogenic bacteria found in the lower smallb: recombinant Bifidobacterium infantis containing pTRKH2-PsT plasmid
plasmid group. *P< 0.05 vs. group a; ▲P< 0.05 vs. group b.
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mammalian animals. These intestinal organisms are
believed to have health-promoting properties for their
host, including increase of the immune response [35], in-
hibition of tumor growth, inhibition of carcinogenesis,
and protection of the host against viral infection [36]. In
addition, Bifidobacterium can be killed easily by antibio-
tics or in oxygen environment in vitro or in vivo [37].
Therefore, it is very safe to use Bifidobacterium infantis
as delivery carrier. In this study, there were no obvious
side effects on tumor-bearing mice after the intravenous
delivery of Bifidobacterium infantis during the whole ex-
periment process, which further proves its safety.
Antiangiogenesis therapy is one of the most important
strategies for treating cancer [5,13]. Tumor angiogenesis
is a complex of coordinated interactions between numer-
ous proteins involved in different signaling pathways.
Each step provides an opportunity for therapeutic inter-
vention. Angiogenesis mediated by VEGF constitutes a
new target for anticancer therapy, which has been
explored through different forms of intervention aimed
at blocking tumor neovascularization. Strategies to in-
hibit tumor angiogenesis include inhibition of angiogenic
factor production and their receptors, inhibition of the
VEGF signaling pathway, inhibition of the binding be-
tween VEGF and its receptors, and inhibition of intracel-
lular transduction of the VEGF signal [10,13,31]. The
KDR is VEGFR-2, which is one of the most important
receptors for binding with VEGF. The structure of
VEGFR-2 contains an intracellular part, a transmem-
brane part, and an extracellular part which are all essen-
tial for signal transporting [14]. The sKDR is the soluble
form of the extramembrane part of VEGFR-2, which has
same high affinity for VEGF but does not conduct signal.
Thus, sKDR can bind with VEGF and compete with nor-
mal VEGFR-2 and can function as dominant negative by
forming inactive heterodimers with membrane-spanning
VEGF receptors [12,38]. To date, many studies have
proven that the specific binding of sKDR with VEGF
could significantly inhibit the blood vessel formation in
tumor tissue, thereby inhibiting the growth, proliferation
and migration of tumor [15,23,31,38].
In this study, in vitro experiment showed that the
Bifidobacterium infantis-mediated sKDR prokaryotic ex-
pression system was successfully constructed and could
express sKDR at both gene and protein levels. The pro-
ducts of this system could significantly inhibit the growth
of HUVECs induced by VEGF. In addition, the in vivo
experiment showed that Bifidobacterium infantis could
specifically target to tumor tissue and express sKDR after
intravenously injected. The blood flow signals and MVD
of the tumor in group c were both lower than those of
the other two groups, showing that the blood vessel for-
mation in group c was significantly inhibited. At thesame time, the tumors of mice in group c showed more
serious necrosis rate and less growth rate. The mice in
group c also exhibited longer survival time. All these
results showed that the Bifidobacterium infantis-
mediated sKDR prokaryotic expression system possessed
anti-angiogenetic effects that further caused tumor ne-
crosis and anti-tumor effects. Although this system could
significantly reduce the MVD, increase the tumor necro-
sis and show greater tumor inhibitive rate, the effects
on tumor volume and tumor weight seems to be week
(Figures 4, 5A). We think the combined treatment of
Bifidobacterium infantis-mediated sKDR prokaryotic ex-
pression system and chemotherapy or radiotherapy may
be more effective and need further study in our future
experiment.
In this study, Bifidobacterium infantis itself showed
anti-tumor effects in some way. The results showed that
the tumor volume in pTRKH2-PsT group was smaller
than that in the control group, and the MVD and signals
of blood flow in the tumor were less in pTRKH2-PsT
group compared with the control group. The mechanism
remains uncertain. Bifidobacterium infantis may be able
to stimulate inflammatory response, induce the accumu-
lation of immune cells, and promote the secretion of
antitumor factors by macrophage. The structure of
Bifidobacterium infantis cell wall had antitumor effects
[22]. The local proliferation of Bifidobacterium infantis
competing with the nutrition of tumor cells may contrib-
ute to its antitumor effects as well. However, the expres-
sion of sKDR may play a more significant role, based on
a comparison of group b and group c.
Conclusion
In this study, the Bifidobacterium infantis-mediated
sKDR prokaryotic expression system was successfully
constructed, and could express sKDR at both gene and
protein levels. The system could not only inhibit the
growth of HUVECs induced by VEGF, but also blood
vessel formation and tumor growth on Lewis lung cancer
mice model. This system showed specific and safe tumor
targeting property. Thus, the Bifidobacterium infantis-
mediated sKDR prokaryotic expression system may be a
promising treatment method for cancer.
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